Abstract Purpose:To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003. Experimental Design: All participants were interviewed by one of two researchers using standardized questionnaires, and their medical records were reviewed by one research nurse.The two main regimens received were cyclophosphamide, methotrexate, and fluorouracil and fluorouracil, epirubicin, and cyclophosphamide. The proportion of cases and controls receiving anthracyclinebased treatment was equivalent, but fewer BRCA1 cases received this treatment than did BRCA2 mutation carriers. Toxicity was documented using the Eastern Cooperative Oncology Group Common Toxicity Criteria for hematologic, infective, and gastrointestinal toxicities. No increase in toxicity was seen in BRCA1/2 mutation carriers. Results: The only significant difference was that neutropenia was less evident in BRCA2 mutation carriers than in either BRCA1 mutation carriers or controls. As a result, there was no requirement for dose reduction among BRCA2 mutation carriers, in contrast to 10 of 39 BRCA1 carriers and 16 of 62 controls (P = 0.02). Conclusions:This result has implications for therapy and indicates that women with mutations in BRCA1 and BRCA2 may be given the same doses of chemotherapy as noncarriers.
BRCA1 and BRCA2 mutation carriers face a high risk of both breast and ovarian cancer due to mutations in these DNA double-strand break repair genes. Adjuvant breast cancer treatments of chemotherapy and radiotherapy rely on killing cells by mechanisms which include inducing DNA damage, affecting cell cycle checkpoints, or cell division, as reviewed by Kennedy et al. (1) . The BRCA1 and BRCA2 genes have been shown to be integrally involved in these pathways, particularly in the repair of DNA double-strand breaks by homologous recombination. It is important to examine the effects of radiation and chemotherapeutic agents in BRCA1 and BRCA2 carriers as one would expect that they could have a greater incidence of normal tissue toxicity from both modalities compared with women with sporadic disease. The accompanying report evaluates the late effects of radiation in a case-control study of BRCA1/2 mutation carriers and sporadic controls in the United Kingdom (17) . In conjunction with that study, the toxicity of chemotherapy was also examined to address the following questions: are BRCA1/2 mutation carriers more at risk of acute toxicity from chemotherapy? Do such individuals experience more severe decreases in blood counts and chemotherapy cycle delays, and would this result in a requirement for alterations to current protocols such as dose reduction or cycle interval alterations to avoid increased toxicity?
Chemotherapeutic drugs are divided by their mechanisms of action, but most include the production of DNA double-strand breaks in their repertoire, often after the induction of interstrand cross-links. As the BRCA genes are known to function in the homologous repair of DNA double-strand breaks, is there evidence that tumor and/or the normal tissues in BRCA heterozygotes have increased sensitivity to specific chemotherapeutic agents?
In vitro data are limited. Studies using brca1-homozygous null murine ES cells have shown increased cell death induced by the alkylating agent, mitomycin C, platinum, and the topoisomerase inhibitors including doxorubicin (which is also an anthracycline) and mitoxantrone compared with wild-type cells (2 -4), but there were no differences for cells treated with antimetabolites. A study of a BRCA2 heterozygous mutant ovarian cancer cell line has shown heightened sensitivity to cisplatin compared with paclitaxel, but this study did not have a wild-type cell line control (5) .
Clinical data are suggestive of enhanced chemosensitivity in homozygous tumor tissues in BRCA mutation carriers, but no prospective data are available. Chappuis et al. (3) and Delaloge et al. (6) both found increased clinical response rates in BRCA carriers compared with controls, when treated for breast cancer with anthracyclines and cyclophosphamide. A larger study by Goffin et al. (7) supported a greater survival benefit for chemotherapeutic effect for breast cancer treatment in BRCA1 mutation carriers than in controls. Improved clinical response rates and survival have also been shown for BRCA mutation carriers versus controls in treatment for ovarian cancer with cisplatin (8) . The basis for this sensitivity seems to be the disruption of cell signaling pathways involving Fanconi anemia genes, one of which, FANCD1, is now known to be BRCA2 (9). This has generated interest in the use of cisplatin in the treatment of BRCA-related cancers and an international trial of carboplatin versus docetaxel in advanced breast cancer in BRCA carriers is under way (known as the BRCA Trial, see http:// www.breakthroughcentre.org.uk/).
Chemotherapeutic regimens for breast cancer in the United Kingdom, during the time that this study was conducted, included the use of several combinations, predominantly cyclophosphamide, methotrexate, and fluorouracil (CMF), fluorouracil, epirubicin, and cyclophosphamide (FEC), and (10, 11) . In the interim, there is a need to determine if conventional chemotherapeutic regimens need to be modified, hence, this study.
Materials and Methods
In this study, we retrospectively evaluated 62 BRCA1/2 mutation carriers and 1:1 matched controls for acute chemotherapeutic toxicity following breast cancer chemotherapy. Case participants were women treated for breast cancer with chemotherapy and/or radiotherapy who were known to carry a mutation in the BRCA1 or BRCA2 genes. They were recruited from three genetics centers as part of the study detailed in the associated article, ''Late toxicity is not increased in BRCA1/2 mutation carriers undergoing breast radiotherapy in the United Kingdom (17) .'' Of the 55 mutation carriers described in that article, 34 received chemotherapy and are included in this study. An additional 28 casecontrol pairs were recruited who received chemotherapy without radiation.
Control participants were recruited from the Breast Units of four centers. Matching was done as described in the accompanying report for the following variables: age F12 years, tumor size, nodal status, receipt of radiation treatment, and duration of follow up from the end of treatment. Type of chemotherapeutic regimen (anthracycline-based or not) was not a matching criterion, as this proved too restrictive. Exclusion criteria were the presence of any family history of premenopausal breast cancer or ovarian cancer or Jewish ancestry, to limit the likelihood of undetected BRCA mutations in the control group. Matching proved challenging due to the paucity of age-appropriate controls, the presence of occult family history, and differences in treatment regimens.
Acute chemotoxicity was assessed by interview using standardized questionnaires based on Eastern Cooperative Oncology Group Common Toxicity criteria (12) and review of medical records. The questionnaires were administered by one of two researchers-either the coordinating clinician or the research nurse. Mucosal, gastrointestinal, hematologic, and infective toxicities were scored according to the Eastern Cooperative Oncology Group scale of Common Toxicity. Records reviewed included chemotherapy prescription sheets and chemotherapy regime; the dosage and timing of treatment were recorded. Laboratory reports of white cell counts, dose reductions, and delays (and the reason for the delay) were reviewed.
Statistical considerations. Nonparametric methods were employed for analysis. Although individual matching was undertaken, matched pairs analysis was not employed, as missing or unknown data items would require that patients be omitted from the analysis. The Kruskal-Wallis test was used for ordinal data when comparing more than two groups c There were 51 denominators for the pairs listed because 11 pairs were excluded in the report for these variables due to atypical matching features (these variables are reported in this manner to maintain the consistency of the description method with the companion article on radiation outcomes, in which matching discrepancies affect long-term cancer outcomes and for which these variables were relevant). All 62 pairs were included in the analysis of acute chemotherapy toxicity events as these matching discrepancies would not affect acute chemotherapy toxicity.
Acute Chemotherapy^Related Toxicity in BRCA1/ 
No correction for multiple testing was employed (13) , and P values must be interpreted with caution in view of the large number of significance tests done. P values >0.10 have been shown as nonsignificant. P values between 0.10 and 0.051 are suggestive of significance and have therefore been displayed. Missing or inapplicable responses were excluded when calculating P values. Unless otherwise indicated, P values in the tables refer to the comparison of all BRCA1 and BRCA2 carriers with control participants. Typical detectable differences (80% or greater power, 5% two-sided significance level) with 62 patients in each group (comparing binomial end points) were: 5% versus 25%, 10% versus 35%, 20% versus 45%, 30% versus 60%, 40% versus 70%, and 50% versus 80%.
Results
Institutions. Sixty-two case-control pairs from four centers (Table 1) were evaluated. The majority of cases were matched with a control from their treating center, although additional recruitment of controls from Guy's Hospital was undertaken to match cases at the Royal Marsden NHS Foundation Trust and St. Mary's Hospitals in five cases, where local matching had been unsuccessful.
Age. Cases were significantly younger than the controls with median ages of 45 for BRCA1 mutation carriers, 47 for BRCA2 mutation carriers, and 51 for controls (Table 1) .
Tumor size. Although matching was undertaken as closely as possible for tumor size (T stage), it was not possible to obtain exact T stage matches in all cases. One T stage difference was therefore accepted, providing that nodal status matched. This resulted in a nonsignificant excess of nine T 1 tumors among case participants which were matched with nine controls who had T 2 tumors. Two T 3 tumors in the cases were matched with T 2 control tumors and two T 4 case tumors were matched with T 3 controls.
Nodal status. Nodal status was matched in addition to T stage as closely as possible. Where nodal status was unknown (when nodes were not dissected or where nodes were found to be clear following neoadjuvant chemotherapy), a match was accepted with a participant who had a node-positive, node-negative, or node-unknown tumor. There is an excess of node-positive tumors among controls but this difference was tolerated due to the fact that this study was examining acute toxicity from chemotherapy and not long-term cancer outcomes.
Overall staging. In keeping with the differences in tumor size matching, there is an excess of case participants with stage I tumors matched to stage II controls. There are also four stage III cases, three of whom were matched to stage II controls. Two stage IV cases were matched to stage III controls.
Surgery. Thirty-six of 62 cases in each group underwent mastectomy. Nine of these in each group also had radiotherapy postoperatively. Twenty-four cases had wide local excision and radiotherapy, and two cases had no surgery but underwent primary treatment with radiation and chemotherapy. These 26 cases were matched with an equivalent number of controls that received conservative surgery and local radiation treatment. Contralateral mastectomies were undertaken in 22 cases but in only 2 controls. Due to this significant difference in surgical treatments, it was not appropriate to examine tumor outcomes such as contralateral tumor rates in this study.
Chemotherapy regimens. Although the type of regimen used was not matched, the proportion of participants receiving anthracycline-based regimens (FEC predominantly) was equivalent in both arms of the study when considering BRCA1 and BRCA2 cases together versus controls. If BRCA1 cases are considered separately from BRCA2 carriers, there is an excess of non -anthracycline-based regimens (CMF) among BRCA1 cases compared with BRCA2 cases (P = 0.03) or controls (P = 0.014).
Endocrine treatments. Thirty of 51 case participants underwent oophorectomy compared with 2 controls. Of these 30, 7 BRCA1 and 8 BRCA2 mutation carriers received tamoxifen in addition. A further 6 received tamoxifen alone. In total, therefore, 36 of 51 cases underwent some form of endocrine manipulation, as compared with 38 of 51 controls receiving tamoxifen (which included the 2 individuals who had oophorectomy).
Toxicities. BRCA2 mutation carriers experienced fewer episodes of neutropenia, and as a result, no alterations in dose, compared with a need for dose reductions in 10 of 39 BRCA1 mutation carriers and 16 of 62 controls (P = 0.02). There were no significant differences in the intervals of dosing required or the proportion of individuals experiencing severe mucosal, infective, or gastrointestinal toxicities in cases versus controls ( Table 2) .
The requirement for dose alteration secondary to toxicity for each regimen is illustrated in Table 3 . Alterations were more common for control participants than for BRCA1/2 carriers when receiving CMF chemotherapy, although not significantly so (P = 0.08), as 44% of controls were affected by dose adjustments for toxicity compared with 23% of BRCA1 mutation carriers, and none of the BRCA2 mutation carriers. The other main regimen used was FEC. Three controls receiving this regimen required dose changes, whereas no BRCA1/2 mutation carriers were affected, but due to the low numbers, this was not a significant difference.
Overlap between dates of chemotherapy regimen completion and the commencement of radiation occurred in the treatment of 10 cases and 7 controls. Of these, 3 of the control participants required dose alterations (due to neutropenia, colitis, and nausea), but this was not needed for BRCA1/2 carriers. Neoadjuvant therapy was received by 7 cases (5 BRCA1 and 2 BRCA2 mutation carriers) and 15 controls.
Discussion
Much attention has been focused on the question of whether women with breast cancer due to inherited mutations in BRCA1 or BRCA2 have a different prognosis from women with sporadic breast cancer. Recent data support a poorer outcome in some BRCA1 carriers, but this is probably only in the subset of breast cancer patients who do not receive chemotherapy (6, 7, 14) , suggesting that BRCA1 heterozygotes may benefit more from chemotherapy than their sporadic counterparts. Survival data in BRCA2 mutation carriers is available in limited numbers, but seems to equate to that of women with sporadic cancers (15) . Given that the possibility of greater tumor-killing benefit of chemotherapy for carriers has been raised, an accompanying question is whether the heterozygous cells are also more sensitive to chemotherapy. This report did not examine long-term cancer outcomes but addressed the question of acute chemotherapyinduced toxicity as documented by objective measures according to the Common Toxicity Criteria (such as hematologic counts) and recorded dose reductions as well as subjective measures of patient recall of gastrointestinal and infective symptoms.
Follow up was significantly shorter for the case group than controls. This may have had the potential to bias the recall of the cases towards more severe events due to the shorter time interval between the event and the recollection. We accept that acute toxicity is difficult to assess retrospectively based on recall alone, but our review of medical notes meant that we could assess basic data such as full blood counts and chemotherapy records, indicating scheduling (to assess the most clinically significant outcome of treatment delays), which were available in 95% of cases across the time interval of the study.
Matching constraints also meant that case participants were younger than controls ( Table 1 ). Given that toxicity may be affected by age, it is possible that these differences may have biased the study towards reduced toxicity in the BRCA mutation carriers, although it is questionable whether a difference of 4 years in median age would account for the differences between BRCA2 mutation carriers and controls. It is also notable that the median ages of cases and controls who required dose alterations due to toxicity were not significantly different (P = 0.05).
Although it was not feasible to match for the type of regimen, the distribution of anthracycline versus non -anthracycline regimens was equivalent in the cases and controls. One-third of women in the case and control arms received anthracyclines, although this was more common in BRCA2 carriers than in BRCA1 carriers.
The main finding of this study is that acute toxicity from chemotherapy was not increased in BRCA1/2 mutation carriers, and that in BRCA2 carriers, hematologic toxicity was less than that seen in controls. It is not likely that the difference in need for dose alterations in BRCA2 mutation carriers reflected a difference in chemotherapeutic regimen compared with controls as the distribution of regimens between these two groups was similar. BRCA1 mutation carriers received less anthracycline-based chemotherapy than either BRCA2 mutation carriers or controls, and it is possible that this could have had an effect on their rate of toxicity, perhaps masking a phenotype similar to that seen in BRCA2 carriers. This possibility is supported by findings from the recent National Epirubicin Adjuvant Trial (16), in which toxicity was seen to be greater in patients receiving CMF compared with those receiving initial anthracyclines. It is not possible to comment on outcomes from other regimens such as platinum-based agents because too few participants received these agents. It would be useful to examine other factors in the treatment regimens of BRCA1/2 mutation carriers for possible confounding factors such as renal function variables, which affect the excretion of some chemotherapeutic agents and thus alter toxicity. Given the age range of the patients, however, it is unlikely that significant renal impairment would be prevalent in this population.
This study is the first to evaluate the acute effects of chemotherapy in BRCA1/2 carriers in the United Kingdom, and indeed, in the world. Although regimen usage will change as more is understood of how best to target BRCA homozygous tumor cells; thus far, treatment does not seem to have been at the expense of heightened toxicity to the heterozygous tissues such as bone marrow, gastrointestinal, and mucosal tissues. This report has provided evidence that there is no increased toxicity from the studied adjuvant regimens for breast cancer in BRCA1/2 mutation carriers. This is reassuring, particularly for BRCA1, because tumors are more often high-grade and estrogen receptor -negative than are sporadic tumors, and in both BRCA1 and BRCA2, breast cancer is more likely to occur at younger ages. These are all indications for adjuvant chemotherapy and this study has provided the first data to indicate that such treatment may be given in a standard dose to such patients. 
